RxDoctor Payments Data

Joshua Sleeper, MD

Urology · Covington, LANPI 1285834234

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $9,695 of the $11,308 with a category attached, or 85.7%. It is spread thinly across 50 manufacturers, the largest accounting for just 18.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $3,858 and has fallen 58.9% since, to $1,587 in 2025.

$11,308in general payments, 2019–2025

Across 289 payments — averaging $39.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neotract Inc.$2K
  • Boston Scientific$857
  • Coloplast$836
  • Medtronic$729
  • Procept Biorobotics Corporation$687
  • Astellas Pharma US Inc$664
  • plus $5K from 44 others

What the payments were for

  • Travel & lodging$1,54014%
  • Food & beverage$9,69586%
  • Education$731%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,308 in reported general payments places this provider in the 85th percentile of 199 urology providers in Louisiana.

See all urology providers in Louisiana

Medicare billing

Part B allowed, 2024
$185,830
Medicare patients
416
Services billed
13,128

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide29$355,587
MyrbetriqMirabegron95$53,241
GemtesaVibegron60$35,565
Testosterone Cypionate101$4,973
Testosterone19$1,399
Alfuzosin Hcl ErAlfuzosin Hcl45$1,214
Solifenacin Succinate20$1,034
Tamsulosin Hcl152$921
Tolterodine Tartrate ErTolterodine Tartrate16$555
Dutasteride17$428
Finasteride13$378
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst20$372
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen54$182
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav13$124
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim57$122

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$664$408,828124 claims
Sumitomo Pharma America, Inc.Gemtesa$236$35,56560 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 199 urology providers in Louisiana.

Other urology in Covington

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →